Compare Tilray Brands Inc (TLRY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Viatris Inc — how do they compare? Tilray Brands Inc trades at $4.27 (market cap $524.07M), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 37.8× Tilray Brands Inc's market cap, and Viatris Inc pays a 2.83% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | VTRS | |
|---|---|---|
Market Cap | $524.07M | $19.79B |
Sector | Health | Health |
52-Week High | $21.00 | $17.39 |
52-Week Low | $4.23 | $8.74 |
Enterprise Value | $621.22M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.23, down 1.63% with bearish technical signals. The company reported revenue growth to $821.31M in 2025 but faces severe profitability challenges with a net loss of $2.19B and negative margins. Recent expansion includes medical cannabis launches in Panama and strategic acquisitions, while analyst consensus shows cautious sentiment with 65% hold ratings.
The outlook remains challenging due to persistent losses and high debt levels, though expansion initiatives and potential regulatory changes offer long-term opportunities. Key risks include execution on profitability, competitive pressures, and cannabis regulatory uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
